<DOC>
	<DOCNO>NCT01148901</DOCNO>
	<brief_summary>This trial design measure improvement hip involvement patient ankylose spondylitis ( AS ) receive 4 dos infliximab . Participants receive infliximab 5 mg/kg ( intravenous perfusion period 2 hour ) Weeks 0 , 2 , 6 , 14 , consistent approve dose regimen describe label . Participants evaluate hip pain , functional capacity stiffness 14 week ( 4 dos ) treatment . Further treatment 4 dos base standard clinical practice determine trial site .</brief_summary>
	<brief_title>Effectiveness Safety Early Treatment With Infliximab Hip Arthritis Associated With Ankylosing Spondylitis ( AS ) ( P06451 )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>18 year age old Ankylosing spondylitis ( AS ) diagnosis Have 3 following : Presence hip pain ( nocturnal inflammatory pain ) Limitation hip mobility Patient 's Global Assessment Visual Analog Scale ( 010 cm ) ≥4 cm . Inadequate response intolerance nonsteroidal antiinflammatory drug ( NSAIDs ) Eligible treat Infliximab ( Remicade® ) Causes coaxalgia coxitis AS , demonstrate image laboratory test Women pregnant nursing plan nurse become pregnant Serious infection like sepsis , abscess . History current certain infection History current certain medical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Ankylosing spondylitis</keyword>
	<keyword>Hip arthritis</keyword>
	<keyword>Infliximab</keyword>
</DOC>